Taiwan Bio Therapeutics
Investors
  1. Home
  2. Investors
  3. Corporate Governance
  4. Board of Directors
  5. Board Resolutions
Corporate Governance
Board of Directors Committees Corporate Governance Officer Major Internal Policies
Financials
Monthly Revenue Financial Reports
Shareholder Services
Major Shareholders Meeting Information Stakeholder Contact Prospectuses Material Information Dividend and Stock
Investor Conference
Interested Parties
Board Composition Board Resolutions Board Execution Status
Date Resolution
May 12
  • Approved the Company’s financial report for the first quarter of 2025.
  • Approved the acquisition of 100% equity in Tract Therapeutics, Inc.
  • Approved the establishment of a U.S. subsidiary and sub-subsidiary.
  • Approved the change of the Company's chief auditor.
  • Approved the compensation for the Company’s managerial officers.
  • Approved the list of employees granted stock options and the number of shares they are entitled to subscribe for under the 2023 employee stock option plan.
Mar. 12
  • Approved the engagement of non-assurance services to be provided by Ernst & Young and its affiliates.
  • Approved the 2024 Business Report and Financial Statements.
  • Approved the appointment of Ernst & Young for the certification of the Company's 2025  financial and tax reports, along with the assessment of the independence and competency of the signing CPAs.
  • Approved the proposal for offsetting the 2024 losses.
  • Approved the amendment to the Articles of Incorporation.
  • Approved the revision of the Company's internal control system and the definition of entry-level employees.
  • Approved the termination of the 2024 private placement of common shares, previously approved by the Annual General Meeting.
  • Approved the private placement of common shares for 2025.
  • Approved the convening of the 2025 Annual General Meeting of Shareholders.
  • Approved the capital injection into the U.S. subsidiary, PhiBio Therapeutics Inc.